4 recruiting, 1 not yet recruiting. 4 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SYS6043: new trials by email Literature Review of SYS6043 trials Research Report on SYS6043
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors SYS6043, bevacizumab, carboplatin - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-10-15 | 2026-09-22 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan - Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 460 | 2026-07-15 | 2026-09-23 |
| Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors SYS6043 - Cancer, Solid Tumor Cancer | Phase 1 | Recruiting | Conjupro Biotherapeutics, Inc. | 386 | 2026-03-03 | 2026-04-07 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors sirolimus (albumin-bound), DP303c, SYS6043 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 444 | 2025-11-13 | 2025-11-28 |
| Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors SYS6043 - Advanced/Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 820 | 2024-12-30 | 2026-02-17 |
Breast Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
CSPC Megalith Biopharmaceutical Co.,Ltd. (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Conjupro Biotherapeutics, Inc. (1)
China (3) · United States (1)